NR3C2 and diabetes mellitus: MR blockade in diabetes has previously been examined in the FIDELIO‐DKD trial, where a cardiovascular benefit was noted in the finerenone group independently of pre‐existing cardiovascular disease (Filippatos et al., 2021).